DE60138222D1 - Modulierung von il-2 und il-15 vermittelten t zellantworten - Google Patents

Modulierung von il-2 und il-15 vermittelten t zellantworten

Info

Publication number
DE60138222D1
DE60138222D1 DE60138222T DE60138222T DE60138222D1 DE 60138222 D1 DE60138222 D1 DE 60138222D1 DE 60138222 T DE60138222 T DE 60138222T DE 60138222 T DE60138222 T DE 60138222T DE 60138222 D1 DE60138222 D1 DE 60138222D1
Authority
DE
Germany
Prior art keywords
agent
cell death
receptor
antagonists
targets
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60138222T
Other languages
English (en)
Inventor
Xian Chang Li
Terry Strom
Xin Xiao Zheng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beth Israel Deaconess Medical Center Inc
Original Assignee
Beth Israel Deaconess Medical Center Inc
Beth Israel Hospital Association
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Deaconess Medical Center Inc, Beth Israel Hospital Association filed Critical Beth Israel Deaconess Medical Center Inc
Application granted granted Critical
Publication of DE60138222D1 publication Critical patent/DE60138222D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
DE60138222T 2000-09-14 2001-09-14 Modulierung von il-2 und il-15 vermittelten t zellantworten Expired - Lifetime DE60138222D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23225100P 2000-09-14 2000-09-14
PCT/US2001/028612 WO2002022805A2 (en) 2000-09-14 2001-09-14 Modulation of il-2- and il-15-mediated t cell responses

Publications (1)

Publication Number Publication Date
DE60138222D1 true DE60138222D1 (de) 2009-05-14

Family

ID=22872402

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60138222T Expired - Lifetime DE60138222D1 (de) 2000-09-14 2001-09-14 Modulierung von il-2 und il-15 vermittelten t zellantworten

Country Status (16)

Country Link
US (2) US20020114781A1 (de)
EP (2) EP1349873B1 (de)
JP (1) JP2004525076A (de)
CN (1) CN1317301C (de)
AT (1) ATE427318T1 (de)
AU (1) AU2001292645A1 (de)
BR (1) BR0113906A (de)
CA (1) CA2422294C (de)
DE (1) DE60138222D1 (de)
ES (1) ES2322936T3 (de)
HK (1) HK1061408A1 (de)
IL (1) IL154925A0 (de)
MX (1) MXPA03002278A (de)
RU (1) RU2280255C2 (de)
WO (1) WO2002022805A2 (de)
ZA (1) ZA200302933B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7247304B2 (en) 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
WO2004069183A2 (en) * 2003-01-31 2004-08-19 Albor Biologics, Inc. Immune regulation based on the targeting of early activation molecules
DE602004031341D1 (de) 2003-07-21 2011-03-24 Transgene Sa Multifunktionelle cytokine
US7534585B2 (en) 2003-07-21 2009-05-19 Transgene S.A. Multifunctional cytokines
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
DE602005016773D1 (de) 2004-01-22 2009-11-05 Merck Patent Gmbh Antikrebs-antikörper mit reduzierter komplementfixierung
PL1899364T3 (pl) 2005-05-17 2020-08-24 University Of Connecticut Kompozycje i sposoby immunomodulacji w organizmie
EP1777294A1 (de) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi Domäin als selektieve und potente Enhancer von IL-15 Aktion durch IL-15Rbeta/gamma, und Hyperagonist (IL15Ralpha sushi -IL15) Fusionsproteine
CN102796743B (zh) 2006-01-13 2015-11-18 美国政府健康及人类服务部国立卫生研究院 用于在哺乳动物细胞中表达的密码子优化的IL-15和IL-15Rα基因
WO2007124331A2 (en) * 2006-04-19 2007-11-01 Virginia Commonwealth University Cardioprotective and other uses of mammalian target of rapamycin (m-tor) inhibitors
WO2008138017A2 (en) * 2007-05-08 2008-11-13 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for modifying t cell immune responses and inflammation
ES2642008T3 (es) 2007-05-11 2017-11-14 Altor Bioscience Corporation Moléculas de fusión y variantes de IL-15
NZ616254A (en) 2007-06-27 2015-04-24 Us Sec Dep Of Health And Human Services Complexes of il-15 and il-15ralpha and uses thereof
JP2009065938A (ja) * 2007-09-14 2009-04-02 Matsumoto Shika Univ タンパク質、破骨細胞分化阻害剤、炎症性骨破壊治療薬、遺伝子、組み替えベクター、及びタンパク質の製造方法
EP2401383B1 (de) * 2009-02-27 2013-09-18 Novartis AG Verfahren zur selektion von ein heterologes protein exprimierenden eukaryontischen zellen
NZ714757A (en) 2009-08-14 2018-07-27 Us Gov Health & Human Services Use of il-15 to increase thymic output and to treat lymphopenia
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
EP3327040B1 (de) 2010-09-21 2021-06-23 Altor BioScience Corporation Multimere il-15-lösliche fusionsmoleküle sowie verfahren zu ihrer herstellung und verwendung
RS60050B1 (sr) * 2011-01-18 2020-04-30 Bioniz Llc Kompozicije za modulaciju aktivnosti gama-c-citokina
DK3578201T3 (da) * 2012-06-28 2023-05-08 Univ Of Central Florida Research Foundation Incorporated Fremgangsmåder og sammensætninger til naturlige dræberceller
HUE058364T2 (hu) 2013-04-19 2022-07-28 Cytune Pharma Citokinbõl származó kezelés redukált vaszkuláris permeabilitási szindrómával
US9959384B2 (en) 2013-12-10 2018-05-01 Bioniz, Llc Methods of developing selective peptide antagonists
EP2915569A1 (de) 2014-03-03 2015-09-09 Cytune Pharma Reinigungsverfahren für Il-15/Il-15Ralpha-basierte Konjugate
WO2016004060A2 (en) 2014-06-30 2016-01-07 Altor Bioscience Corporation Il-15-based molecules and methods of use thereof
CN113234138A (zh) 2014-08-11 2021-08-10 德里尼亚公司 选择性地活化调节性t细胞用于治疗自身免疫病的修饰的il-2变体
WO2017062685A1 (en) 2015-10-09 2017-04-13 Bioniz, Llc Modulating gamma - c -cytokine activity
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
WO2017096262A1 (en) 2015-12-04 2017-06-08 Jomoco, Corp. Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
CN106591368A (zh) * 2016-10-12 2017-04-26 郑州大学 携带il‑15r/il‑15融合基因的b亚群腺病毒11载体及其构建和用途
JP2019533449A (ja) 2016-10-21 2019-11-21 アルター・バイオサイエンス・コーポレーション 多量体ｉｌ−１５に基づく分子
JP2019532996A (ja) 2016-11-08 2019-11-14 デリニア，インコーポレーテッド 自己免疫疾患を処置するためのｉｌ−２変異体
CA3060443A1 (en) 2017-04-19 2018-10-25 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
RU2698048C2 (ru) * 2017-10-03 2019-08-21 Закрытое Акционерное Общество "Биокад" МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
US20220332780A1 (en) 2019-09-10 2022-10-20 Obsidian Therapeutics, Inc. Ca2-il15 fusion proteins for tunable regulation
WO2021222178A1 (en) * 2020-04-27 2021-11-04 The Trustees Of Indiana University Adjunct therapy for suppressing immune response against gene therapy
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
CN114773433B (zh) * 2022-06-23 2022-09-06 北京肿瘤医院(北京大学肿瘤医院) 一种cd25靶向多肽、分子探针及应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011684A (en) * 1985-09-05 1991-04-30 Beth Israel Hospital Association Lysing or blocking unwanted cells with IL-2 receptor-specific binding substance
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
EP0495639A1 (de) 1991-01-16 1992-07-22 Schering Corporation Verwendung von Interleukin-10 in der adaptiven Immunotherapie von Krebs
IL101353A0 (en) * 1991-04-03 1992-11-15 American Home Prod Pharmaceutical compositions for treating diabetes
CA2144648A1 (en) 1992-09-18 1994-03-31 Mario Clerici Restoration of immunocompetency to t helper cells in hiv infected patients
US5552303A (en) * 1993-03-08 1996-09-03 Immunex Corporation DNA encoding epithelium-derived T-cell factor
US5574138A (en) * 1993-03-08 1996-11-12 Immunex Corporation Epithelium-derived T-cell factor
US5747024A (en) * 1993-03-08 1998-05-05 Immunex Corporation Vaccine adjuvant comprising interleukin-15
IL111004A (en) * 1993-09-30 1998-06-15 American Home Prod Oral formulations of rapamycin
US5795966A (en) 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
ES2243995T3 (es) * 1996-04-26 2005-12-01 Beth Israel Deaconess Medical Center, Inc. Antagonistas de interleucina-15.
ATE295736T1 (de) * 1997-02-21 2005-06-15 Vlaams Interuniv Inst Biotech Verwendung von interleukin-15
DE19823351A1 (de) 1997-05-16 1998-12-10 Krause Hans Mittel zur Verhinderung der Zellapoptose bei Krankheiten

Also Published As

Publication number Publication date
WO2002022805A2 (en) 2002-03-21
EP2123672A1 (de) 2009-11-25
US20020114781A1 (en) 2002-08-22
EP1349873A2 (de) 2003-10-08
EP1349873B1 (de) 2009-04-01
IL154925A0 (en) 2003-10-31
AU2001292645A1 (en) 2002-03-26
WO2002022805A3 (en) 2003-07-17
ES2322936T3 (es) 2009-07-02
CN1478098A (zh) 2004-02-25
ZA200302933B (en) 2004-07-14
HK1061408A1 (en) 2004-09-17
US7579439B2 (en) 2009-08-25
BR0113906A (pt) 2004-12-07
MXPA03002278A (es) 2004-12-03
CN1317301C (zh) 2007-05-23
CA2422294A1 (en) 2002-03-21
JP2004525076A (ja) 2004-08-19
ATE427318T1 (de) 2009-04-15
CA2422294C (en) 2012-12-04
RU2280255C2 (ru) 2006-07-20
US20040185048A1 (en) 2004-09-23

Similar Documents

Publication Publication Date Title
DE60138222D1 (de) Modulierung von il-2 und il-15 vermittelten t zellantworten
NZ535616A (en) Indolymaleimide derivatives as protein kinase c inhibitors
PL316942A1 (en) Novel pharmaceutic compositions based on taxoides
HRP20110169T1 (hr) Upotreba [d-meala]3-[etval]4-ciklosporina za liječenje infekcija hepatitisom c
YU61502A (sh) Nukleozidni analozi karboksamidno modifikovanih bicikličnih baza
AR028982A1 (es) COMPOSICIoN FARMACÉUTICA, SU USO EN LA FABRICACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO O PROFILAXIS DE UNA CONDICIoN MEDIADA POR ALDOSTERONA Y EL PROCESO PARA SU PREPARACIoN .
TW200701981A (en) Heterocyclic antiviral compounds
DE60236541D1 (de) Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1
HUP0104390A2 (hu) Alfa-2B vagy alfa-2B/2C adrenerg receptorokra nézve szelektív agonista aktivitással rendelkező imidazolszármazékok és alkalmazásuk
TR200000015T2 (tr) Bileşikler ve metodlar
DE69307977T2 (de) Stabilisierte Derivate von Vitamin D2 und D3 enthaltende pharmazeutische Zusammensetzungen
BR0315620A (pt) Derivados de n-benzodioxolil, n-benzodioxanil e n-benzodioxepinil arilcarboxamida, e composições farmacêuticas compreendendo os mesmos
HK1045456A1 (en) Novel therapeutic use of viral inflammation modulatory protein in blocking xenograft rejection
DK0972519T3 (da) Immuntolerance-inducere
ATE277639T1 (de) Zusammensetzungen von adenosin a1 agonisten und 5ht3 agonisten
SE8001425L (sv) Cytostatiskt verkande lekemedel resp farmaceutiska beredningar
MY125300A (en) Synergistic combination for treatment of viral-mediated diseases
BR0113140A (pt) Antagonistas de receptor de ccr1 não peptìdico em combinação com ciclosporina a para o tratamento da rejeição de transplante de coração
ATE113949T1 (de) Alpha-adrenergische rezeptorantagonisten.
ATE114310T1 (de) Alpha-adrenergische rezeptorantagonisten.
BR0215498A (pt) Composição farmacêutica compreendendo uma glitazona e um ácido 4-oxobutanóico e o seu uso para o tratamento de diabetes
ATE109483T1 (de) Alpha-adrenergische rezeptorantagonisten.
TR200102196T2 (tr) Mono-asiloksi aralkil nöromuskular relaksanları.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition